John Bryant

Top papers

• A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

  Soonmyung Paik, Steven Shak, Gong Tang, et al.·2004·New England Journal of Medicine
  ↗ 6,334OA
• Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer

  Bernard Fisher, Stewart Anderson, John Bryant, et al.·2002·New England Journal of Medicine
  ↗ 6,188OA
• Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

  Edward H. Romond, Edith A. Perez, John Bryant, et al.·2005·New England Journal of Medicine
  ↗ 5,344OA
• Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

  Soonmyung Paik, Gong Tang, Steven Shak, et al.·2006·Journal of Clinical Oncology
  ↗ 2,568
• Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

  Bernard Fisher, John Bryant, Norman Wolmark, et al.·1998·Journal of Clinical Oncology
  ↗ 2,185
• Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation

  Bernard Fisher, Jong‐Hyeon Jeong, Stewart Anderson, et al.·2002·New England Journal of Medicine
  ↗ 1,378OA
• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  Bernard Asselain, William E. Barlow, John M.S. Bartlett, et al.·2017·The Lancet Oncology
  ↗ 1,118OA
• American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

  Eric P. Winer, Clifford A. Hudis, Harold J. Burstein, et al.·2004·Journal of Clinical Oncology
  ↗ 1,034OA
• Which Pneumococcal Serogroups Cause the Most Invasive Disease: Implications for Conjugate Vaccine Formulation and Use, Part I

  William P. Hausdorff, John Bryant, Peter R. Paradiso, et al.·2000·Clinical Infectious Diseases
  ↗ 870
• Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

  Bernard Fisher, James J. Dignam, John Bryant, et al.·1996·JNCI Journal of the National Cancer Institute
  ↗ 869OA
• Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

  Elizabeth Tan-Chiu, Greg Yothers, Edward H. Romond, et al.·2005·Journal of Clinical Oncology
  ↗ 805
• Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28

  Eleftherios P. Mamounas, John Bryant, Barry C. Lembersky, et al.·2005·Journal of Clinical Oncology
  ↗ 713